These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2884466)

  • 41. Screening of blood donations for hepatitis C virus antibody.
    Kimber RJ
    Med J Aust; 1990 Jun; 152(11):613. PubMed ID: 2112223
    [No Abstract]   [Full Text] [Related]  

  • 42. [Hepatitis C virus antibodies (anti-HCV) prevalence rate in anti-HBc-negative blood donors].
    Baur P; Roelcke D
    Beitr Infusionsther; 1991; 28():25-6. PubMed ID: 1725631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Serological study on hepatitis C (HCV) in 4371 blood donors].
    Arnone M; Pinducciu G; Usai M; Pitzus F; Pintus L
    Ann Ig; 1990; 2(5):353-8. PubMed ID: 1715726
    [No Abstract]   [Full Text] [Related]  

  • 44. Current status of posttransfusion hepatitis.
    Alter HJ; Holland PV; Purcell RH
    Pathobiol Annu; 1980; 10():135-56. PubMed ID: 6777742
    [No Abstract]   [Full Text] [Related]  

  • 45. Prospective assessment of donor blood screening for antibody to hepatitis C virus and high-titer antibody to HBcAg as a means of preventing posttransfusion hepatitis.
    Takano S; Omata M; Ohto M; Satomura Y
    Hepatology; 1993 Aug; 18(2):235-9. PubMed ID: 8393422
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Donor serum alanine aminotransferase activity and the risk of transfusion-associated hepatitis.
    Lenes BA; Tomasulo P; Alter HJ; Holland PV
    N Engl J Med; 1983 Mar; 308(12):723. PubMed ID: 6402702
    [No Abstract]   [Full Text] [Related]  

  • 47. Use of a table-top analyzer for predonation screening for alanine aminotransferase--a cost-effective approach?
    Saxena S; Endahl GL; Shulman IA
    Am J Clin Pathol; 1988 Sep; 90(3):296-9. PubMed ID: 3137804
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-B post-transfusion hepatitis with hepatitis B core antibodies in donor blood.
    Katchaki JN; Siem TH; Brouwer R
    N Engl J Med; 1982 Sep; 307(10):628-9. PubMed ID: 6810169
    [No Abstract]   [Full Text] [Related]  

  • 49. [Currently available means for the prevention of post-transfusion hepatitis and criteria for their application].
    Bedarida G; Cambiè G; D'Agostino F; Sterza G
    Ric Clin Lab; 1984; 14 Suppl 1():37-60. PubMed ID: 6429830
    [No Abstract]   [Full Text] [Related]  

  • 50. Non-B post-transfusion hepatitis associated with hepatitis B core antibodies in donor blood.
    Vyas GN; Perkins HA
    N Engl J Med; 1982 Mar; 306(12):749-50. PubMed ID: 6801510
    [No Abstract]   [Full Text] [Related]  

  • 51. Should donor blood be screened for elevated alanine aminotransferase levels? A cost-effectiveness analysis.
    Silverstein MD; Mulley AG; Dienstag JL
    JAMA; 1984 Nov 23-30; 252(20):2839-45. PubMed ID: 6436522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decrease in reported posttransfusion hepatitis. Contributions of donor screening for alanine aminotransferase and antibodies to hepatitis B core antigen and changes in the general population.
    Chambers LA; Popovsky MA
    Arch Intern Med; 1991 Dec; 151(12):2445-8. PubMed ID: 1747001
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatitis C--screening of blood donations.
    Walsh TJ
    Ir Med J; 1991 Jun; 84(2):41-2. PubMed ID: 1716620
    [No Abstract]   [Full Text] [Related]  

  • 54. Epidemiological studies with anti-hepatitis C virus.
    Bove JR
    Hepatology; 1991 Feb; 13(2):387-8. PubMed ID: 1847354
    [No Abstract]   [Full Text] [Related]  

  • 55. Antibodies to hepatitis C virus and surrogate marker testing of blood donors to prevent non-A, non-B hepatitis.
    Kakaiya R; Stephans J; Carnahan G; Ahmed P; Miller WV
    Transfusion; 1991 Oct; 31(8):780-1. PubMed ID: 1656555
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical value of the guanase screening test in donor blood for prevention of posttransfusional non-A, non-B hepatitis.
    Ito S; Tsuji Y; Kitagawa N; Akihiko I; Syundo J; Tamura Y; Kishi S; Mori H
    Hepatology; 1988; 8(2):383-4. PubMed ID: 3128469
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FDA and surrogate testing for non-A,non-B hepatitis.
    Biswas R
    Transfusion; 1989 Oct; 29(8):750. PubMed ID: 2508278
    [No Abstract]   [Full Text] [Related]  

  • 58. Concerns about ALT testing.
    Kosmin M
    Transfusion; 1982; 22(6):535-7. PubMed ID: 6815842
    [No Abstract]   [Full Text] [Related]  

  • 59. Serum alanine aminotransferase (ALT) assay and incidence of posttransfusion non-A,non-B hepatitis.
    Barcena Marugan R; Zamora C; Moreno A; Erdozain Sosa JC; Perez Hernandez F; Lopez San Roman A
    Transfusion; 1989 Oct; 29(8):751. PubMed ID: 2508279
    [No Abstract]   [Full Text] [Related]  

  • 60. Alanine aminotransferase screening and hepatitis C virus antibody.
    Burckhardt JJ; Friedli H; Gardi A; Heiniger HJ
    Lancet; 1990 Aug; 336(8712):447-8. PubMed ID: 1974981
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.